Natco Pharma launches drug in the US for the treatment of adult patients with multiple myeloma

The capsules, a thalidomide analogue, are indicated for the treatment of adult patients with multiple myeloma who have received at least two prior therapies including lenalidomide and a proteasome inhibitor and have demonstrated disease progression on or within 60 days…






